paxilline has been researched along with MEA 2a in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bocciardi, R; Borrello, MG; Bourget, I; Fischer, S; Mograbi, B; Pasini, B; Pierotti, MA; Romeo, G; Rossi, B | 1 |
1 other study(ies) available for paxilline and MEA 2a
Article | Year |
---|---|
The multiple endocrine neoplasia type 2B point mutation switches the specificity of the Ret tyrosine kinase towards cellular substrates that are susceptible to interact with Crk and Nck.
Topics: Adaptor Proteins, Signal Transducing; Animals; COS Cells; Cytoskeletal Proteins; Drosophila Proteins; Multiple Endocrine Neoplasia Type 2a; Oncogene Proteins; Paxillin; Phosphoproteins; Point Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-crk; Proto-Oncogene Proteins c-ret; Receptor Protein-Tyrosine Kinases; Signal Transduction; src Homology Domains; Substrate Specificity | 1997 |